N. V. Lomakin

AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial

Andrey A. Ivashchenko, Kirill Dmitriev, Natalia Vostokova et al. · Clinical Infectious Diseases · 2020 · 258 citations · Full text

May 2020, Russian Ministry, Viral Diagnostics +12

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek et al. · Circulation · 2022 · 112 citations · Full text

The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study

N. V. Lomakin, G. Musaev, Elena S. Pasechnik et al. · Inflammation Research · 2021 · 53 citations · Full text

Endometrial hyperplasia-related inflammation: its role in the development and progression of endometrial hyperplasia

Anatoly V. Kubyshkin, E.P. Kovalenko, S. V. Litvinova et al. · Inflammation Research · 2016 · 52 citations

Inflammation, Uterine Fibroids, Endometriosis +9

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

Gregory G. Schwartz, Michael Szarek, Vera Bittner et al. · Diabetes Care · 2021 · 32 citations · Full text